Clint T Allen

List of Publications by Year
in descending order

110 papers	3,992 citations	109321 35 h-index	138484 58 g-index
112 all docs	112 docs citations	112 times ranked	5586 citing authors

#	Article	IF	Citations
1	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight, 2019, 4, .	5.0	168
2	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3KÎ´/Î³. Cancer Research, 2017, 77, 2607-2619.	0.9	165
3	Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. Cancer Immunology Research, 2017, 5, 1141-1151.	3.4	160
4	Human papillomavirus and oropharynx cancer: Biology, detection and clinical implications. Laryngoscope, 2010, 120, 1756-1772.	2.0	154
5	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clinical Cancer Research, 2020, 26, 1420-1431.	7.0	151
6	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. Oncologist, 2019, 24, 1259-1269.	3.7	127
7	Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis and Rheumatology, 2021, 73, 1886-1895.	5.6	125
8	Î”Np63 Versatilely Regulates a BroadNF-ÎºBGene Program and Promotes Squamous Epithelial Proliferation, Migration, and Inflammation. Cancer Research, 2011, 71, 3688-3700.	0.9	119
9	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncology, 2016, 58, 59-70.	1.5	115
10	Established T Cellâ€“Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. Cancer Immunology Research, 2016, 4, 1061-1071.	3.4	114
11	Nuclear Factor-ÎºBâ€“Related Serum Factors as Longitudinal Biomarkers of Response and Survival in Advanced Oropharyngeal Carcinoma. Clinical Cancer Research, 2007, 13, 3182-3190.	7.0	110
12	Role of activated nuclear factor-ÎºB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head and Neck, 2007, 29, 959-971.	2.0	99
13	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. Cancer Immunology Research, 2019, 7, 401-413.	3.4	99
14	Galectin-1â€“driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. Journal of Clinical Investigation, 2019, 129, 5553-5567.	8.2	94
15	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. OncoImmunology, 2018, 7, e1395996.	4.6	90
16	PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. , 2020, 8, e000450.		79
17	Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. Oncotarget, 2017, 8, 55804-55820.	1.8	75
18	Aberrant IKKÎ± and IKKÎ² cooperatively activate NF-ÎºB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene, 2014, 33, 1135-1147.	5.9	74

#	Article	IF	Citations
19	Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. Cancer Immunology Research, 2016, 4, 611-620.	3.4	73
20	TNF-Î± Promotes c-REL/Î”Np63Î± Interaction and TAp73 Dissociation from Key Genes That Mediate Growth Arrest and Apoptosis in Head and Neck Cancer. Cancer Research, 2011, 71, 6867-6877.	0.9	71
21	Bortezomib-Induced Apoptosis with Limited Clinical Response Is Accompanied by Inhibition of Canonical but not Alternative Nuclear Factor-ÎºB Subunits in Head and Neck Cancer. Clinical Cancer Research, 2008, 14, 4175-4185.	7.0	69
22	Antigen processing and presentation in cancer immunotherapy. , 2020, 8, e001111.		66
23	Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Antiâ€“CD44-Based NIR-PIT. Molecular Cancer Research, 2017, 15, 1667-1677.	3.4	64
24	Comparative Analysis of Tumorâ€Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer. Otolaryngology - Head and Neck Surgery, 2012, 147, 493-500.	1.9	63
25	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers, 2015, 7, 2397-2414.	3.7	61
26	Pulsed High-Intensity Focused Ultrasound Enhances Apoptosis and Growth Inhibition of Squamous Cell Carcinoma Xenografts with Proteasome Inhibitor Bortezomib. Radiology, 2008, 248, 485-491.	7.3	56
27	Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer. Clinical Cancer Research, 2009, 15, 2361-2372.	7.0	55
28	Laryngotracheal Stenosis: Risk Factors for Tracheostomy Dependence and Dilation Interval. Otolaryngology - Head and Neck Surgery, 2017, 156, 321-328.	1.9	54
29	Emerging insights into head and neck cancer metastasis. Head and Neck, 2013, 35, 1669-1678.	2.0	53
30	The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope, 2012, 122, 144-157.	2.0	52
31	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. OncoImmunology, 2018, 7, e1466018.	4.6	51
32	The p53 Homologue Î”Np63Î± Interacts with the Nuclear Factor-ÎºB Pathway to Modulate Epithelial Cell Growth. Cancer Research, 2008, 68, 5122-5131.	0.9	50
33	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigenâ€“Specific T Cells. Clinical Cancer Research, 2020, 26, 679-689.	7.0	49
34	Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies. , 2018, 6, 59.		43
35	Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. OncoImmunology, 2018, 7, e1471440.	4.6	43
36	mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. Oncotarget, 2015, 6, 36400-36417.	1.8	43

#	Article	IF	Citations
37	WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. OncoImmunology, 2018, 7, e1488359.	4.6	41
38	Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition. OncoImmunology, 2019, 8, e1638207.	4.6	39
39	Induction of tumor regression by intratumoral STING agonists combined with antiâ€“programmed deathâ€ L1 blocking antibody in a preclinical squamous cell carcinoma model. Head and Neck, 2017, 39, 1086-1094.	2.0	38
40	Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function. Cancer Immunology Research, 2019, 7, 282-291.	3.4	38
41	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
42	Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. Oncotarget, 2018, 9, 4109-4119.	1.8	34
43	Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Locally Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 447-454.	0.8	33
44	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. ELife, 2020, 9, .	6.0	32
45	The PDâ€1 and PDâ€L1 pathway in recurrent respiratory papillomatosis. Laryngoscope, 2018, 128, E27-E32.	2.0	31
46	ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. OncoImmunology, 2020, 9, 1710398.	4.6	30
47	Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPVâ^' and HPV+ Head and Neck Cancers to TNFÎ±, TRAIL, and Radiation Therapy. Clinical Cancer Research, 2019, 25, 6463-6474.	7.0	28
48	Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. Oral Oncology, 2017, 71, 87-94.	1.5	26
49	Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms. OncoImmunology, 2018, 7, e1404216.	4.6	26
50	Endoscopic Keel Placement to Treat and Prevent Anterior Glottic Webs. Annals of Otology, Rhinology and Laryngology, 2013, 122, 672-678.	1.1	24
51	Murray secretion scale and fiberoptic endoscopic evaluation of swallowing in predicting aspiration in dysphagic patients. European Archives of Oto-Rhino-Laryngology, 2017, 274, 2513-2519.	1.6	24
52	Defining Clinical Subgroups in Relapsing Polychondritis: AÂProspective Observational Cohort Study. Arthritis and Rheumatology, 2020, 72, 1396-1402.	5.6	24
53	Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. Oral Oncology, 2019, 90, 38-44.	1.5	22
54	Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. EBioMedicine, 2021, 67, 103345.	6.1	21

#	Article	IF	Citations
55	Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. , 2021, 9, e002128.		20
56	Clinical Assessment and Treatment of the Dysfunctional Larynx after Radiation. Otolaryngology - Head and Neck Surgery, 2013, 149, 830-839.	1.9	18
57	Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays. Journal of Immunological Methods, 2017, 440, 12-18.	1.4	18
58	Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-Î² blockade in HPV-unrelated head and neck cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	18
59	Pools of programmed deathâ€ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. Head and Neck, 2016, 38, 1176-1186.	2.0	17
60	Anatomic Derkay Score Is Associated with Voice Handicap in Laryngeal Papillomatosis in Adults. Otolaryngology - Head and Neck Surgery, 2016, 154, 689-692.	1.9	16
61	Mechanisms of resistance to T cellâ€based immunotherapy in head and neck cancer. Head and Neck, 2020, 42, 2722-2733.	2.0	16
62	The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma. Biomarker Research, 2021, 9, 42.	6.8	16
63	Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages. Cancer Research, 2021, 81, 5977-5990.	0.9	14
64	Office-Based vs Traditional Operating Room Management of Recurrent Respiratory Papillomatosis. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 55.	2.2	13
65	Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis. , 2021, 9, e003113.		12
66	Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer. Head and Neck, 2018, 40, 1321-1334.	2.0	11
67	How patients with an intact immune system develop head and neck cancer. Oral Oncology, 2019, 92, 26-32.	1.5	11
68	Hoarseness After Metastatic Colon Cancer Treatment. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 881.	2.2	10
69	Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes. Communications Biology, 2021, 4, 1416.	4.4	10
70	How Enhancing Immunity to Lowâ€Risk <scp>HPV</scp> Could Cure Recurrent Respiratory Papillomatosis. Laryngoscope, 2021, 131, 2041-2047.	2.0	9
71	The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations. Oral Oncology, 2022, 132, 106012.	1.5	8
72	CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer. Clinical Cancer Research, 2015, 21, 942-943.	7.0	7

#	Article	IF	Citations
73	Evaluating the utility of serological testing in laryngotracheal stenosis. Laryngoscope, 2017, 127, 1408-1412.	2.0	7
74	Biologics for the Treatment of Recurrent Respiratory Papillomatosis. Otolaryngologic Clinics of North America, 2021, 54, 769-777.	1.1	7
75	Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer. Biomarker Research, 2021, 9, 90.	6.8	7
76	Prevalence of Diabetes Mellitus and Its Impact on Disease Severity in Adult Recurrent Respiratory Papillomatosis. Otolaryngology - Head and Neck Surgery, 2013, 149, 603-607.	1.9	5
77	Risk stratification in endoscopic airway surgery: is inpatient observation necessary?. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2014, 35, 747-752.	1.3	5
78	Immunotherapy for HPV Malignancies. Seminars in Radiation Oncology, 2021, 31, 361-370.	2.2	5
79	Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity. JCI Insight, 2022, 7, .	5.0	5
80	Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNFÎ± Resistance in Head and Neck Cancers. Molecular Cancer Research, 2022, 20, 867-882.	3.4	5
81	Tracheal Mass. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 291.	2.2	4
82	Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis. Npj Vaccines, 2021, 6, 86.	6.0	4
83	Determining if T cell antigens are naturally processed and presented on HLA class I molecules. BMC Immunology, 2022, 23, 5.	2.2	4
84	Pathology Quiz Case 1. JAMA Otolaryngology, 2011, 137, 526.	1.2	3
85	A Submucosal True Vocal Fold Mass. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 1025.	2.2	2
86	First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).. Journal of Clinical Oncology, 2021, 39, TPS6092-TPS6092.	1.6	2
87	Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Head and Neck, 2022, 44, .	2.0	2
88	Trismus and voice change after starting tuberculosis treatment. IDCases, 2021, 26, e01307.	0.9	1
89	Pathology Quiz Case 2. JAMA Otolaryngology, 2009, 135, 1056.	1.2	0
90	Pathology Quiz Case 2. JAMA Otolaryngology, 2010, 136, 311.	1.2	0

#	Article	IF	Citations
91	Squamous-cell carcinoma. , 0, , 686-692.		0
92	Posterior Subglottic Mass in a Patient With a History of Rectal Adenocarcinoma and Lung Metastases. JAMA Oncology, 2020, 6, 1967.	7.1	0
93	Abstract 3900: Nuclear c-REL displaces p73 in partnering with DNp63 to suppress p21 expression and promote proliferation in head and neck cancer. , 2010, , .		0
94	Abstract 5005: Combined targeting of IKKÎ± and Î² effectively suppresses NF-Î¹B activation, cell survival and migration in head and neck squamous cell cancers. , 2011, , .		0
95	Immunohistochemical Analysis of NF-Î¹B in Human Tumor Tissue. Methods in Molecular Biology, 2015, 1280, 459-468.	0.9	0
96	Abstract B087: Cyclic dinucleotide: A novel adjuvant for squamous cell carcinoma. , 2016, , .		0
97	Abstract 1477: Targeting immunosuppressive myeloid cells in oral cavity cancer with the PI3KÎ´/Î³ isoform inhibitor duvelisib. , 2016, , .		0
98	Abstract 1448: MDSC depletion delays primary tumor growth in syngeneic models of oral cavity cancer. , 2016, , .		0
99	Abstract 2637: Anti-tumor activity of cisplatin is enhanced by PD-1 blockade in preclinical models of head and neck squamous cell carcinoma. , 2017, , .		0
100	Abstract 3996: MDSC depletion combined with CTLA-4 blockade cause tumor regression in a syngeneic model of oral cavity cancer. , 2017, , .		0
101	Abstract 1696: High-dose versus low-dose fractionated ionizing radiation to enhance antigen-specific antitumor immunity. , 2017, , .		0
102	Abstract B199: Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy. , 2018, , .		0
103	Inflammation and Head and Neck Squamous Cell Carcinoma. Current Cancer Research, 2018, , 353-364.	0.2	0
104	Abstract 3906: Inhibition ofNF-kB Inducing Kinase (NIK) to supressNF-kB alternative pathway and cell migration in HNSCC. , 2018, , .		0
105	Abstract 1762: Shifting the tumor microenvironment with first-in-class semaphorin 4D mab for combination immunotherapy. , 2018, , .		0
106	Abstract PR09: Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies. , 2018, , .		0
107	Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy. , 2019, , .		0
108	Abstract 3206: Host immunity following near infrared photoimmunotherapy is enhanced with PD-1 checkpoint blockade to eradicate established highly antigenic tumors. , 2019, , .		0

#	Article	IF	Citations
109	Improving responses to immunotherapy in head and neck squamous cell carcinoma. , 2020, , 107-133.		0
110	Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC). Current Otorhinolaryngology Reports, 2022, 10, 96-107.	0.5	0